pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-147b |
Genomic Coordinates | chr15: 45433050 - 45433129 |
Description | Homo sapiens miR-147b stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | |
---|---|
Mature miRNA | hsa-miR-147b |
Sequence | 49| GUGUGCGGAAAUGCUUCUGCUA |70 |
Evidence | Experimental |
Experiments | Cloned |
Putative Targets |
miRNA Expression profile | |
---|---|
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | ALDH5A1 | ||||||||||||||||||||
Synonyms | SSADH, SSDH | ||||||||||||||||||||
Description | aldehyde dehydrogenase 5 family member A1 | ||||||||||||||||||||
Transcript | NM_001080 | ||||||||||||||||||||
Other Transcripts | NM_170740 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on ALDH5A1 | |||||||||||||||||||||
3'UTR of ALDH5A1 (miRNA target sites are highlighted) |
>ALDH5A1|NM_001080|3'UTR 1 GATTCTTTGGTTCTTTAAAAAAATTTAAAAGGAGACTTATCTACATATATAGGTACATGCCATCCATTATTTTAAATAAA 81 CTAATAGGTTTTCAGAATTATGAATTTTTCAGAACTCATCCAGTCCTTGTAATCTTAAACAGATGCAAATCCTACCCCTG 161 CCCTTAATGTAACTAGGGACCAATATGTGCCACGTGCCTGTGGCTGCAGACTCCCAGAGAACCAGCACTGGGTTTACAGA 241 ATGAGGCCCTGGCTCCCCACCACAGCCCCAGCTGCCTCAGAGCAGGCACAGCACAAGGCAGGCCCAGCCCCATGGGCCGT 321 CACAAAGGCTTGATCACTGCCTGGGCAGTGGCACAACCATCCCCCATGTCGCTACAGAACATGGGCCCAGAGCACCTTGA 401 AGGAGACCCTTGACTGTGACTGGCAGGCAGGTGAGGGGCACAGCACCCCTCCCCGGCATCTGCCAGCTCAGCACAGAAGA 481 CACCGAATGTGCATCTGGAGGTGTTGCGGCAGAGGTTTGAGTGAACCCTCTTTCAAAGACAATAAATAGCACAGAATTGT 561 CCGTGCTTCTGTGAGGCACGAAGGAGCACCTCTCCCTATTCCTGAACCATATTTTAATTGATGCCTTTATTGTCCCAAAT 641 TTACCACTTAAAGAATTCTATTTTCATTTCTGTCCTGTTTGCCACTTCATTTCATTTCCTTGAGTAAATGAGCTGAAGTG 721 TAAAGCAAAGAATAGCAGAAGCAGCTTGGTAGGATGGAAGGCACGCAGTGGCATGGCCTGGCTCCTTCCCTGAGTGGCCT 801 TGTTGCCTTGGGCGTGTGTTCAGCACCTCCCATCCCATGGATACAGTGGAGATTCCATACAGGCCTTACTTAGCTCCTTG 881 CGATACTGTGAGCCAGAGAGAAAGTAAAAGCACTTCACAAAAAAATGAAAATTCTAAGGACATACAAGAGCCATTGTTAC 961 GAGCAGCACCGCCCAGCCCTTCCTTGCCTACTGTCAGTGGCTTTGCCAAGATGGGAGGAGGCCAGTGCCCACTTGCCCAC 1041 CGACCTGAGCCTGAGTAAGTGGCTGTCACCTGAGCCTGTTCTTTCTGTCCTGGTGTGGTGCTGCTCCCTCACCTCCAAAA 1121 GAGCAAAAGTACTTTCACCACAGTCAACCCAAAAGGGAAAGAATTTCTGTAATTGCCAACCCACTTTGTAGAAGAGGCAT 1201 GAGCCCTTGAATTTCAGGCACCTTTTATCTAATGAGAGTTTTTACAGCTCATCATTCAAATAACGCACAAAAAACAAAAG 1281 CCGCTATGACCGGCGTTGCCTCTCACTTTGAAAGAAAGACTCCGTAATCTTAAACAGATGCAAATCCAATTAGGCGGCCA 1361 AGTAGGTGGAGACGAAGCACCTTCCTTTCCCCATCTCTGTCTGTGTAGACTCCACTTACATCTTGTGGTTATTCTGGGTT 1441 GTGGAAGGAAAATGTGAATGAAAGTAGTGCTGGATGCAATTACTCCTGAACCCCACCTAGGATTTAACATCCCTCATTGA 1521 GCCACTGGGAAGCTATGGTTGAGTAACTAAAGGTCTGGCAAGACCCTGGGCACACAGGGAGCTGCCTAGCATCTGGCCTG 1601 GAGTGTACTAGCCACATTCCCAAGGTCCCAAGGAGAAGGAAGAGCTGAAATTCATCTCCTAGTGACAGTGCCCCGGCCCT 1681 GTCAAGAATCACATACTCAGCATTTTGACAGTTAATGTCTTCTCTTTATTTGTGTAGTTTTTAGGTGGTTTTATATAACA 1761 TTTTAATTACTTGTGATTTAGATGTATCCATCCTTTTTCTATTAAGAATACAAATGCTGGGCTGGGCACAGTGGCTCACG 1841 CCTGTAATCCCAACACCTTGGGAGGCCAAGGCAGGCAGATCACGACATCAGGAGATCGAGACCATCCTGGCTAACACGGT 1921 GAAACCCCGTCTCTACTAAAAATACAAAAAAAATTAGTCGGATGTGGTGGCAGGTGCCTGTAGTCCCAGCTACTCTGGAG 2001 GCTGAGGCAGGAGAATGGCGTGAACCCAGGAGGCGGAGCTTGCAGTGAGCAGAGATCACGCCACTGCACTCCAGCCTGGA 2081 TGACAGAGCGAGACTCCGCCTCAAAAAAAGAATACAAATGCTCCAACATTATTTTTTATAACTCTGGATTACCGATGCTG 2161 AGATGTGTGCAGGAATACTTCCAAATAAATTTTTAACATTGTAAGCCAGTAGATTCTTTGGCTGGGTGGCAAATTTTGAG 2241 TCTTCTTGCATATTTGGCTCATGGGTTCATAAATTGAGGCCAGAGACTCATTGTATATCCTTGATCAATTTTCTAATTAA 2321 AGGAAATAGCTTATTGTTTAGTAAAATGGCCCTTGGTTGTGGGAAGAAAGAGAATTATTTTTAACTGAACGTTTTTGTTG 2401 TTTTTTAAATAAAGTAGCCATATGTAACGGGATTTTAAAAATATATACATTTTACAACATGGACTAGAAAAGGACCATTA 2481 GATCAGGGGTTGGCAAACTATGGCCCACGAATCAAACCTGGCCTGCCACCTGTTTTTATACAACCTGTGAGCTAAGAATG 2561 GTTTATATGTTTTCAAATGATTGGGCAGAAAATCAAAAGAAGAACAATATTTCATGACACCTGAAAATTCTATGAAATTC 2641 AGATTTCAGTGTCCATAAACAAAATGTTATTAGAGCATAGCCACACCCATTCATTTATGGTATTGTCTGGGACTGCTTTC 2721 TTGGCAGAGTTGAATAGTTGGGACAGGGACAGTATAGCCTGCAAAGCCTAAAAGATTTACTACTTGTCTCCTTAAAGAAA 2801 AAGTTTGCCAGCTCCTGATCTAGACCAAGAGGGAGATATTGACCTTACTTGCATTTATCCGGCATTATTTCAACACCTCC 2881 TGTGAAGAAAGTACTTTTCTGGCATAGCTACCGTGAGTTCTCAGCAGGAACTTCCCAGCGATGATAATGTACATGAAATT 2961 AGCCACGTAACAAGAGTCTATTTGCCTTGAAAAAACAATTATCCTTGAACTTCCTCCAGCTATGCAGGGATTCTCATTAA 3041 AGAGCTGATCTGCATCTGTTTATCCATTTTAGTAGCTTTTAAATATGATTTTATGTGAAGTGCCATTTCTTTATTCTACT 3121 AAAGAGAGACAGCAGAAATAAAGATCAGAAGCAAATGTGAGCAAATCTGTTTTACTGTTAACTTCAATTATGAACTTGAA 3201 ATTGTGCCACATGACTTTTTCCTCTAAAAACTGGATCCTAGTGTTTTAATTACCTGTGTGCAGCTATTTTAAATAGCATT 3281 TTACTTGAATAATATGTATGTTGTCATTGTTTCATGCTATACTTTGTGGGATAAAACTTGGGAATGAGTGTGGTAAGAAA 3361 TTTATAAAGTTTTGCTTTTAAAACGTGGACATAACTCATTTTTCTAGTTTTTGACAATTGTGTGTTTTAGTGTCTAGTCT 3441 GCAGAGAGCTGTGTGATTAATAAACGTGGAATTAACAGAATTTCCTCTCCCTGTA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | A549 |
Location of target site | 3'UTR |
Tools used in this research | MicroCosm , TargetScan |
Original Description (Extracted from the article) |
...
"Interestingly
... - Bertero T; Grosso S; Robbe-Sermesant K; et al., 2012, PloS one. |
Article |
- Bertero T; Grosso S; Robbe-Sermesant K; et al. - PloS one, 2012
Specificity of interaction between a microRNA (miRNA) and its targets crucially depends on the seed region located in its 5'-end. It is often implicitly considered that two miRNAs sharing the same biological activity should display similarity beyond the strict six nucleotide region that forms the seed, in order to form specific complexes with the same mRNA targets. We have found that expression of hsa-miR-147b and hsa-miR-210, though triggered by different stimuli (i.e. lipopolysaccharides and hypoxia, respectively), induce very similar cellular effects in term of proliferation, migration and apoptosis. Hsa-miR-147b only shares a "minimal" 6-nucleotides seed sequence with hsa-miR-210, but is identical with hsa-miR-147a over 20 nucleotides, except for one base located in the seed region. Phenotypic changes induced after heterologous expression of miR-147a strikingly differ from those induced by miR-147b or miR-210. In particular, miR-147a behaves as a potent inhibitor of cell proliferation and migration. These data fit well with the gene expression profiles observed for miR-147b and miR-210, which are very similar, and the gene expression profile of miR-147a, which is distinct from the two others. Bioinformatics analysis of all human miRNA sequences indicates multiple cases of miRNAs from distinct families exhibiting the same kind of similarity that would need to be further characterized in terms of putative functional redundancy. Besides, it implies that functional impact of some miRNAs can be masked by robust expression of miRNAs belonging to distinct families.
LinkOut: [PMID: 23028679]
|
MiRNA-Target Expression Profile | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
18 hsa-miR-147b Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT037742 | NDUFA4 | NDUFA4, mitochondrial complex associated | 5 | 2 | ||||||||
MIRT054214 | ALDH5A1 | aldehyde dehydrogenase 5 family member A1 | 4 | 1 | ||||||||
MIRT054215 | MCM3 | minichromosome maintenance complex component 3 | 4 | 1 | ||||||||
MIRT054216 | COL4A2 | collagen type IV alpha 2 chain | 4 | 1 | ||||||||
MIRT054217 | IER5 | immediate early response 5 | 4 | 1 | ||||||||
MIRT054218 | SDHD | succinate dehydrogenase complex subunit D | 6 | 3 | ||||||||
MIRT464191 | VGLL4 | vestigial like family member 4 | 2 | 4 | ||||||||
MIRT473140 | MLLT1 | MLLT1, super elongation complex subunit | 2 | 2 | ||||||||
MIRT473189 | MITF | melanogenesis associated transcription factor | 2 | 2 | ||||||||
MIRT477858 | DYRK2 | dual specificity tyrosine phosphorylation regulated kinase 2 | 2 | 2 | ||||||||
MIRT493593 | HMGCS1 | 3-hydroxy-3-methylglutaryl-CoA synthase 1 | 2 | 2 | ||||||||
MIRT497529 | ZNF607 | zinc finger protein 607 | 2 | 2 | ||||||||
MIRT535210 | PKIA | cAMP-dependent protein kinase inhibitor alpha | 2 | 4 | ||||||||
MIRT557509 | GPR27 | G protein-coupled receptor 27 | 2 | 2 | ||||||||
MIRT684000 | FOLR1 | folate receptor 1 | 2 | 2 | ||||||||
MIRT688820 | CAPZB | capping actin protein of muscle Z-line beta subunit | 2 | 2 | ||||||||
MIRT699227 | SLCO3A1 | solute carrier organic anion transporter family member 3A1 | 2 | 2 | ||||||||
MIRT755585 | CPEB2 | cytoplasmic polyadenylation element binding protein 2 | 1 | 1 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|